Inhalation Sciences receives 125,000 EURO funding in cross-European research project on inhaled antibiotics and antibiotic resistance
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

Inhalation Sciences receives 125,000 EURO funding in cross-European research project on inhaled antibiotics and antibiotic resistance

(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Formulations for Improved Delivery of Antimicrobials’ (APRINHA). ISAB is one of seven organizations collaborating on this project, including RISE (the Research Institutes of Sweden.) ISAB announced that it had collaborated with RISE on a joint funding proposal for the project on June 9, 2022. The project will run for 36 months. It is being coordinated by the University of Zurich (UZH).

The unmet need for a targeted, efficacious inhaled antibiotic treatment for the growing number of patients hospitalized with lower respiratory tract infections (LRTIs) has become increasingly clear following the Covid-19 pandemic. The APRINHA project aims to address that unmet need. It will develop new inhaled formulations of an antibiotic that can both treat LRTIs and help reduce antibiotic resistance. The new formulations aim to improve drug deposition, retention, and penetration.

The project will last 36 months. Seven organizations are part of the consortium taking part, including RISE, the Research Institute of Sweden. All bring outstanding expertise in inhalation and pulmonary drug delivery with strong track records in contributing to multidisciplinary cross-border research projects. In this project, ISAB will collaborate with the inhalation team at RISE and be using its in vivo PreciseInhale equipment in RISE research facilities to carry out pharmacokinetic (PK) studies of the new formulations.

Manoush Masarrat, CEO ISAB: “We are pleased to be playing a part and would like to thank the team at the Institute of Medical Microbiology at UZH for initiating and coordinating the project. The unmet need for better formulations of antibacterial inhalation products that are active against drug-resistant respiratory infections is urgent. This project addresses that need.”

Read ISAB’s June 9 2022 Press Release on its joint funding proposal to APRINHA with RISE here.

Bifogade filer

Nyheter om Inhalation Sciences

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien Inhalation Sciences

Senaste nytt